The nation of Zimbabwe has turned down a significant US health deal valued at $367m (272 million pounds) over five years over Washington's request for confidential data.
This move became public after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson has since explained that the US was seeking health data for research and profit while refused to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued negotiations to secure a deal suitable to all parties so the nation's vital HIV programme can be sustained.
Wider Background
Zimbabwe's decision follows a similar situation in Kenya, where a court suspended a similar health funding agreement following legal challenges were filed about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance transparency and accountability.
As per statements, Sixteen African countries have so far signed these new health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the end products would be available to our citizens if a future health crisis arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending systems already established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This system is intended to ensure that when a country contributes its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage continued discussions with our American counterparts on how subsequent collaboration might be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but urged that negotiations must proceed considering a large portion of the country's Aids initiatives depended on foreign aid.
"If specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
This impasse underscores the continuing tensions between receiving much-needed international aid and protecting national sovereignty in an increasingly interconnected world.